Latest Teriparatide Stories
OXFORD, England, April 23, 2015 /PRNewswire/ -- Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive
Data Presented at the American Society of Bone and Mineral Research 2014 Annual Meeting THOUSAND OAKS, Calif., Sept.
Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016 THOUSAND OAKS, Calif. and BRUSSELS, Sept.
Data Include Eight Year Analyses of Bone Mineral Density Results for Prolia® (Denosumab) and Further Evidence for Significant Bone-Building With Romosozumab THOUSAND OAKS, Calif., Sept.
THOUSAND OAKS, Calif. and BRUSSELS, Jan.
- A serpent whose bite was fabled to produce intense thirst.